trending Market Intelligence /marketintelligence/en/news-insights/trending/M7vZLkkyb2AfO8plxZr_rA2 content esgSubNav
In This List

Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Fuji Pharma acquires 4.2% of biosimilar developer company Alvotech for $50M

Fuji Pharma Co. Ltd. acquired a 4.2% stake in Iceland-based biopharmaceutical company Alvotech for about $50 million.

Fuji Pharma and Alvotech entered into a partnership in November 2018 to develop and commercialize Alvotech's biosimilar portfolio in Japan. Under the partnership, Alvotech agreed to develop and supply multiple biosimilars, while Fuji will register and commercialize the assets in Japan.

According to Alvotech, the chairman of Tokyo-based Fuji Pharma will join the board of Alvotech following the investment.

Alvotech develops biosimilars to provide cost-competitive products to patients across the globe.